Vavilovskii Zhurnal Genet Selektsii
June 2025
The nucleolus is a large membraneless subnuclear structure, the main function of which is ribosome biogenesis. However, there is growing evidence that the function of the nucleolus extends beyond this process. While the nucleolus is the most transcriptionally active site in the nucleus, it is also the compartment for the location and regulation of repressive genomic domains and, like the nuclear lamina, is the hub for the organization of inactive heterochromatin.
View Article and Find Full Text PDFTumor cells of acute lymphoblastic leukemia (ALL) may have various genetic abnormalities. Some of them lead to a complete loss of certain genes. Our aim was to reveal biallelic deletions of genes in Ph-negative T-ALL.
View Article and Find Full Text PDFThe action of 2-(1-arylethylidene)malononitriles on 2-nitro-1-benzo[]chromenes in the presence of EtN and MoO·2HO results in naphtho[2,1-]furans containing an allylidenemalononitrile unit in the α-position. The reaction proceeds with contraction of the pyran ring via a cascade carba-Michael addition/retro-oxa-Michael reaction/tautomerization/S2/oxidation process. In contrast, the reaction of 2-nitro-1-benzo[]chromenes with the cyclic Knoevenagel adduct derived from 1-indanone and malononitrile leads to dihydroindeno[1,2-]xanthenes.
View Article and Find Full Text PDFThe landscape of chromosomal aberrations in the tumor cells of the patients with B-ALL is diverse and can influence the outcome of the disease. Molecular karyotyping at the onset of the disease using chromosomal microarray (CMA) is advisable to identify additional molecular factors associated with the prognosis of the disease. Molecular karyotyping data for 36 patients with Ph-negative B-ALL who received therapy according to the ALL-2016 protocol are presented.
View Article and Find Full Text PDFPrimary mediastinal B-cell lymphoma (PMBCL) is the only non-Hodgkin's lymphoma variant responding to immune checkpoint inhibitor (ICI) therapy, approximately in half of the cases; however, no molecular markers predicting a response to ICI therapy in PMBCL have been described so far. In this study, we assessed the incidence of the loss of heterozygosity (LOH), elevated microsatellite alteration at selected tetranucleotides (EMAST), and microsatellite instability (MSI) in the tumor genomes of 72 patients with PMBCL undergoing high-dose chemotherapy treatment at the National Research Center for Hematology (Moscow, Russia). Tumor DNA was isolated from biopsy samples taken at diagnosis.
View Article and Find Full Text PDF